1660-95-3

应用筛选条件

关键词:'1660-95-3'

显示 1-2 共 2 条结果关于 "1660-95-3" 范围论文

A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.

Do-Youn Oh et al.

Investigational new drugs, 30(3), 1164-1174 (2011-03-16)

To confirm the efficacy and toxicity of Erlotinib in combination with Gemcitabine and Capecitabine when used as a first-line therapy in metastatic/recurrent pancreatic cancer (PC). Locally advanced PC was excluded. Erlotinib was given at a dose of 100 mg daily

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Andrew T Chan et al.

Gastroenterology, 136(7), 2127-2136 (2009-02-24)

Variants in the cytochrome P450 2C9 (CYP2C9) gene are associated with impaired metabolism of celecoxib. We examined the influence of CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants on dose-related response or toxicity in a randomized trial of celecoxib. We identified individuals

1/1